Charming Medical FY2026: Revenue Slides 23%, Stock Still Halted, Material Weaknesses Flagged
MCTA has more than doubled off its 52-week low of $4.3 on elevated volume (4.9× avg).
Summary
Charming Medical's FY2026 20-F shows revenue down 22.7% to $4.8M, a net loss, and material internal control weaknesses. The stock remains halted since November 2025, and a new Nasdaq delisting rule adds risk.
Key Events · Earnings and Guidance · MCTA
-
Revenue Declines 22.7%
Total revenue fell to $4.8 million from $6.2 million, driven by a 24.4% drop in beauty and wellness services. Customer count and average spending both decreased.
-
Net Loss of $22,648
The company swung from a $1.2 million profit to a small net loss, as operating expenses remained flat while revenue declined.
-
Material Weaknesses in Internal Controls
Management identified material weaknesses related to lack of U.S. GAAP expertise, no internal audit function, and IT deficiencies. Disclosure controls were deemed ineffective.
-
Stock Trading Halted Since November 2025
The SEC suspended trading due to alleged social media manipulation, and Nasdaq has kept the halt in place pending additional information. The company states it did not authorize any promotional activity.
Analysis · MCTA · Industrial Applications And Services
In its first annual report since the IPO, Charming Medical discloses a 22.7% revenue decline to $4.8 million and a swing to a small net loss. The stock has been halted since November 2025 over alleged social media manipulation, and the filing reveals material weaknesses in internal controls. While IPO proceeds have temporarily removed going concern doubts, a new Nasdaq delisting risk looms under the $5 million minimum market value rule. The CEO has locked up her shares and surrendered super-voting stock, but the business is shrinking and the stock remains untradeable.
At the time of this filing, MCTA was trading at $29.36 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $438.5M. The 52-week trading range was $4.30 to $31.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.